Since, in addition to its growth-promoting actions, insulin-like growth factor-I (IGF-I) has rapid vasoactive actions, we investigated the effects of IGF-I on whole-cell ATP-sensitive K + (K ATP ) currents of rat mesenteric arterial smooth muscle cells. IGF-I (10 or 30 nM) reduced K ATP currents activated by pinacidil or a membrane permeant cAMP analogue. Inhibition of phospholipase C, protein kinase C, protein kinase A, mitogen-activated protein kinase or mammalian target of rapamycin (mTOR) did not prevent the action of IGF-I. However, inhibition of K ATP currents by IGF-I was abolished by the tyrosine kinase inhibitor genistein or the phosphoinositide 3-kinase inhibitors, LY 294002 and wortmannin. Intracellular application of either phosphatidylinositol 4,5-bisphosphate (PIP 2 ) or phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) increased the K ATP current activated by pinacidil and abolished the inhibitory effect of IGF-I. Thus, we show regulation of arterial K ATP channels by polyphosphoinositides and report for the first time that IGF-I inhibits these channels via a phosphoinositide 3-kinase-dependent pathway.
Introduction
Insulin-like growth factor-I (IGF-I) acts through the IGF-I receptor to stimulate cell proliferation, transformation, and to protect cells from apoptosis [1, 2] . Cultured human intestinal smooth muscle cells release IGF-I, which stimulates their growth by activation of both mitogen-activated protein kinase (MAP kinase) and phosphoinositide 3-kinase (PI 3-kinase) signalling cascades [3] . In addition to its metabolic and growth-promoting properties, IGF-I has rapid vasoactive effects which range from vasoconstriction to vasodilation depending on the vascular bed, vessel size and species [4] [5] [6] [7] . In rat mesenteric arteries, IGF-I potentiates the vasoconstriction induced by arginine vasopressin [8] , and in primary cultures of smooth muscle cells from these arteries IGF-I increases intracellular Ca 2+ concentration [6] . Some of the rapid effects of IGF-I may occur through actions on ion channels and it has been suggested that modulation of K + channel activity may underlie some of these vasoactive effects [5] . Further, insulin or IGF-I can prevent leptininduced activation of ATP-sensitive K + (K ATP ) channels in rat CRI-G1 insulin-secreting cells [9] . In arterial smooth muscle, modulation of K ATP channels contributes to the effects of a wide range of vasoconstrictor and vasodilator agents on arterial diameter [10] , raising the possibility that IGF-I might also affect K ATP channels to underlie part of its rapid effects on the vasculature. Here have therefore investigated the effects of IGF-I on K ATP channels of rat mesenteric arterial smooth muscle cells.
Materials and methods

Preparation of arterial smooth muscle cells.
Single smooth muscle cells were isolated enzymatically from mesenteric arteries of male adult Wistar rats rendered unconscious by exposure to a rising concentration of CO 2 , and killed by exsanguination, as described previously [11] . The care of the animals conformed to the requirements of the UK Animals (Scientific Procedures) Act 1986. Cells were stored at 4°C, and used on the day of preparation. Cells had a mean membrane capacitance of 14.3 0.3 pF (n = 88). 
Solutions and chemicals
Results
Inhibition of K ATP current by IGF-I
To minimize contamination by voltage-dependent K + channels, whole-cell K ATP currents were recorded at -60 mV in symmetrical K + (140 mM) solutions. Application of 10 M pinacidil, a K ATP channel opener, induced steady-state currents of -140 ± 20 pA which were reduced by 23.9 ± 2.0 % (n = 9) by 10 nM IGF-I (Fig.1 ). The remaining current was blocked by 10 M glibenclamide, a selective blocker of K ATP channels at this concentration [10] . Increasing the concentration of IGF-I to 30 nM did not significantly increase its inhibitory effect (Fig. 1C) . Similar reductions in current by IGF-I were observed when K ATP current was activated either by the membrane permeant cAMP analogue db-cAMP (Fig. 1B,C) , or by 20 M levcromakalim (16.7 ± 2.0 %).
Tyrosine-kinase and PI 3-kinase are involved in the action of IGF-I IGF-I binds to the IGF-I receptor, causing tyrosine auto-phosphorylation, which can in turn activate several downstream pathways [12, 13] . To test whether this auto-phosphorylation step is involved in the IGF-I induced inhibition of K ATP currents we applied IGF-I in the presence of 10 M genistein, a tyrosine-kinase inhibitor. In all experiments with inhibitors applied in the extracellular solution, the inhibitor was applied approximately 10 min before application of IGF-I and was present throughout its application. Genistein effectively abolished the K ATP current inhibition by IGF-I (1.3 ± 0.7%, n = 5, Fig. 2A , B), consistent with a requirement for tyrosine phosphorylation.
Auto-phosphorylation of the IGF-I receptor can lead to activation of PI 3-kinase. Application of either 10 M LY 294002 or 10 nM wortmannin, both of which show selective inhibition of PI 3-kinase at these concentrations [14] , greatly attenuated the inhibitory effect of IGF-I, reducing it to 5.4
1.9% and 3.4 1.7% respectively (Fig. 2) , consistent with the inhibitory effect of IGF-I involving PI 3-kinase.
IGF-I inhibition is not sensitive to blockade of PLC, PKA or PKC.
IGF-I receptor activation stimulates PLC-1 [15] and stimulation of PLC-linked receptors inhibits cloned cardiac-type K ATP channels without the activation of PKC, apparently through depletion of PIP 2 [16] . We have shown that activation of PKC is involved in the inhibition of arterial K ATP channels by angiotensin II (Ang II) and endothelin-1 (ET-1) [11, 17] . We therefore investigated the effects of U 73122, which gives half-inhibition of PLC-mediated Ca 2+ responses in rat portal vein cells at 0.25 M [18] . In the presence of U73122, at either 1 or 10 M, IGF-I still inhibited K ATP current by 22.6 1.6% and 20.5 2.3% respectively (n = 5 and 9, Fig. 3B,F) . Likewise, after applying the PKC inhibitor Ro 31-8220 (1 M), IGF-I still inhibited K ATP current by 20.7 3.4% (Fig. 3A, F) . Ro 31-8220 causes half-inhibition of mixed PKC isoforms at 5 nM [19] , and we have found that it abolishes PKC-mediated effects of Ang II in rat mesenteric arterial smooth muscle cells at 1 M (unpublished observations). Thus, although PKC can inhibit K ATP channels of rat mesenteric arterial smooth muscle, neither PLC nor PKC appear to be involved in the effect of IGF-I.
In human intestinal smooth muscle IGF-I activates the G-protein G i2 to cause inhibition of adenylyl cyclase and so decrease cAMP levels [1] . We have also shown that tonic activation of rat mesenteric arterial K ATP channels by PKA is inhibited by Ang II, and this component of the Ang II action on K ATP channels is prevented in the presence of 5 M PKA inhibitor peptide 5-24 (PKA-IP) [11, 20] . To investigate whether a similar mechanism contributes to the action of IGF-I, we examined its effect in cells dialyzed with intracellular solution containing 5 M PKA-IP. Figures 3E, F show that IGF-I inhibited K ATP current as effectively in cells dialysed with PKA-IP as in control cells, suggesting that PKA is not involved in channel inhibition by IGF-I.
IGF-I inhibition is not sensitive to blockade of MAP kinase or mTOR.
Other pathways stimulated following IGF-I receptor activation include GTP-bound Ras leading to activation of MAP kinase [12, 13] and activation of phosphoinositide-dependent protein kinase (PDK) which may subsequently activate p70 S6 kinase (p70 S6k ) possibly via the mTOR dependent pathway [21, 22] . To evaluate the involvement of MAP kinase in IGF-I induced inhibition of K ATP currents we used PD 98059, which gives half-maximal inhibition of MAP kinase activation at 2 M [23] . Figures 3C and F show that in the presence of 10 M PD 98059, IGF-I inhibited K ATP current by 20.6 2.7% (n = 6), not significantly different from its effect in the absence of the MAP kinase inhibitor.
In cultured porcine aortic smooth muscle, IGF-I up-regulates the expression of the IGFbinding protein 5 through the activation of p70 S6k . The activation of p70 S6k is via a PI 3-kinase and mTOR-dependent pathway [24] . To investigate the possible involvement of this pathway in the effects of IGF-I on K ATP , we tested the effect of the immunosuppressant rapamycin, which selectively inhibits mTOR, and abolishes activation of p70 S6k in aortic smooth muscle cells at 11 nM [25] . In these experiments, cells were dialyzed with pipette solution containing 50 nM rapamycin. Figures 3D and F shows that K ATP current inhibition by IGF-I was not affected in rapamycin-treated cells, suggesting that a PI 3-kinase-and mTOR-dependent activation of p70 S6k is not involved. PIP 2 or PIP 3 prevent K ATP current inhibition by IGF-I Since IGF-I inhibition of K ATP channels appears to involve PI 3-kinase but none of the downstream signalling pathways investigated above, we considered the possibility that PI 3-kinase might affect channel activity by changing phosphoinositide levels. PIP 2 exerts a major effect on K ATP channel inhibition by ATP, reducing ATP sensitivity by up to 1000-fold [26, 27] , and in recombinant systems receptor-mediated hydrolysis of PIP 2 can inhibit the activity of pancreatic and cardiac K ATP channels [16, 26] . Since PI 3-kinase converts PIP 2 to PIP 3 , it is possible that activation of PI 3-kinase by IGF-I reduces the concentration of PIP 2 , perhaps local to the K ATP channel, so reducing channel activity. If this were so, it might be possible to prevent IGF-I induced K ATP channel inhibition by adding PIP 2 to the intracellular solution to mask a local fall in PIP 2 . We therefore investigated the effects of IGF-I in cells dialysed with intracellular solution containing 5 M PIP 2 . Figure 4A and C shows that PIP 2 increased the size of K ATP currents. In PIP 2 -dialysed cells, the mean K ATP current (normalised to membrane capacitance to allow for variations in size between cells) in the presence of 10 M pinacidil was 12.3 1.8 pA/pF compared to 7.2 0.5 pA/pF in control cells (P<0.01). PIP 2 also greatly reduced the inhibitory effect of IGF-I on K ATP current (Fig. 4A, D) .
Like PIP 2, PIP 3 can increase the activity of K ATP channels of pancreatic beta cells, and it has been suggested recently that some of the modulatory effects on K ATP channel activity attributed to changes in PIP 2 might in fact occur through consequent changes in the level of PIP 3 [28] . Activation of PI 3-kinase would be expected to increase PIP 3 levels, and we therefore investigated the effects of PIP 3 on K ATP channel activity. Dialysis of cells with 5 M PIP 3 had effects quite similar to PIP 2 . K ATP current was increased in PIP 3 -dialysed cells (Fig. 4C) , and the inhibitory action of IGF-I was blocked (Fig. 4B, D) . These findings suggest that, as for pancreatic K ATP channels, PIP 3 can activate arterial K ATP channels, but suggest that generation of PIP 3 by PI 3-kinase does not contribute directly to the inhibitory action of IGF-I.
Discussion
Our results showing a tyrosine-kinase dependent inhibition of K ATP currents by IGF-I are the first demonstration, to our knowledge, that a growth factor can cause rapid modulation of smooth muscle K ATP channels. Binding of IGF-I activates its receptor's intrinsic tyrosine kinase activity, stimulating two main signaling pathways, the PI 3-kinase and MAP kinase cascades, which mediate most of the known cellular effects of IGF-I [12, 13] . The IGF-I receptor can also couple to the G-protein G i2 to cause inhibition of adenylyl cyclase and a G γ-mediated activation of MAP kinase [1, 29] . It is unlikely that either PKA or MAP kinase are involved as application of either the PKA inhibitor peptide 5-24 or PD 98059 had any effect on IGF-I inhibition of K ATP current. In contrast, pretreatment of cells with either LY 294002 or wortmannin virtually abolished the inhibitory effect of IGF-I providing evidence for a role of PI 3-kinase. Without knowing the full range of signaling activities regulated by PI 3-kinase in mesenteric arterial smooth muscle cells, it is difficult to define the precise mechanism through which IGF-I mediates its effects. However, we show that PKC is not involved and the inability of rapamycin or Ro 31-8220, which in addition to inhibiting PKC blocks MAPKAP kinase-1 and p70 S6 kinase at similar concentrations [19] , to inhibit the effects of IGF-I indicates that the PKB/mammalian target of rapamycin (mTOR)/p70
S6k pathway is also not involved. K ATP channel activity is very sensitive to membrane PIP 2 levels. Indeed receptor-driven hydrolysis of PIP 2 can reduce activity of cloned K ATP channels of the pancreatic and cardiac types [26] . The lack of effect of the PLC inhibitor, U 73122, on the effects of IGF-1 in the present study indicate that hydrolysis of PIP 2 by PLC is not responsible for channel regulation. PIP 2 levels could also fall as a consequence of conversion to PIP 3 by PI 3-kinase. Although estimates suggest that the PI 3-kinase pathway uses only a small fraction of the PIP 2 pool compared to that mediated by activation of PLC [30] , it is possible that discrete PI 3-kinase-sensitive pools of PIP 2 exist that regulate channel activity. Since PIP 3 also increased the K ATP current and prevented its inhibition by IGF-1, we would expect that in addition to a fall in PIP 2 that would be inhibitory on channel activity, PI 3-kinase activation would also elevate PIP 3 levels, potentially enhancing channel activity. Since PIP 2 and PIP 3 have similar potencies for K ATP channel activation [31] , the IGF-1-dependent depletion of PIP 2 would have to dominate over that of the increase in PIP 3 in the immediate vicinity of the channel to explain the observed inhibition. Alternatively IGF-1 may cause channel inhibition through a PI 3-kinase-dependent pathway that is unaffected by the inhibitors we have used. In this case, the effect of PIP 2 or PIP 3 in blocking inhibition by IGF-1 could result simply from their robust activation of the channels and a masking of the inhibitory effect. Our current data add to the growing body of evidence demonstrating PI 3-kinasedependent regulation of K ATP channels and provide insight into the mechanisms underlying the rapid vasoactive effects of IGF-1. 
